Bioprocessed Black Rice Bran and Balloon Flower Root Cooperatively Regulate IgE, Epithelial Signaling, and Th1/Th2 Balance to Induce Therapeutic Response in a Mouse Model of Atopic Dermatitis

TL;DR

This study shows that a combination of bioprocessed black rice bran and balloon flower root can reduce inflammation and improve symptoms in a mouse model of atopic dermatitis.

Contribution

The novel contribution is the discovery of a synergistic immunomodulatory effect of BRB-F and BFR-F on multiple immune pathways in atopic dermatitis.

Findings

BRB-F and BFR-F reduced IgE production and mast cell degranulation in vitro.

The BRB-F:BFR-F mixture improved skin lesions and reduced serum IgE by up to 87.1% in mice.

The treatment suppressed Th2 cytokines and partially restored Th1 cytokine expression in mice.

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by epidermal barrier dysfunction and dysregulated immune responses, particularly an imbalance between T helper type 1 (Th1) and type 2 (Th2) cytokines. Natural products with immunomodulatory activity have attracted increasing attention as potential strategies for regulating allergic inflammation. In this study, we investigated the immunomodulatory effects of bioprocessed black rice bran (BRB-F) and bioprocessed balloon flower root (BFR-F). In vitro assays using human B cells, mast cells, and keratinocytes were conducted to evaluate IgE production, mast cell degranulation, and epithelial inflammatory mediator release. The efficacy of the BRB-F:BFR-F mixture was further evaluated in BALB/c mice with 2,4-dinitrochlorobenzene (DNCB)/Dermatophagoides farinae extract (DFE)-induced AD-like dermatitis. BRB-F and BFR-F suppressed IgE production, attenuated mast cell degranulation and thymic stromal lymphopoietin (TSLP) release, and reduced keratinocyte-derived inflammatory mediators (thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC), and IL-6). In mice, dietary supplementation with the BRB-F:BFR-F mixture (10–80 mg/kg/day) dose-dependently improved clinical skin lesions and histopathological changes, with serum IgE reduced by up to 87.1% at the highest dose. The treatment significantly suppressed Th2 cytokine mRNA expression in ear tissue (IL-4, IL-5, and IL-13) by 37.2%, 32.7%, and 34.0%, respectively, compared with the positive control. In contrast, splenic Th1 cytokine mRNA expression (IL-2, IL-12, and IFN-γ) was partially restored by 37.1%, 22.5%, and 18.7%, respectively. These findings indicate that BRB-F and BFR-F modulate multiple immune pathways and help restore Th1/Th2 immune balance, suggesting their potential as functional materials for regulating immune dysregulation associated with AD.

Figures